Abstract
Introduction
Prostate cancer (PCa) is the most common malignancy in men and is a leading cause of cancer related morbidity [1, 2] . Since the introduction of prostate-specific antigen (PSA) testing in the late 1980s there has been a steady migration toward lower stage and grade disease [3] . However, the trade-off from this migration was substantial over-diagnosis and over-treatment of cancers that may not have caused harm. Appreciation of this potential downside has gradually led to a more conservative approach in the treatment of low-risk disease. As a result surgery, as well as other radical treatment options, is increasingly reserved for patients with intermediate and high-risk disease [4] . Over the past decade there has been a demonstrable shift in the management of PCa in the UK with increasing use of surgery for younger patients with high-risk disease [4, 5] . In the US literature, where the robotic approach is better-established, a 'reverse stage migration' has been
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demonstrated in prostatectomy cohorts with centres such as Memorial-Sloan Kettering Cancer
Centre reporting the proportion of men undergoing radical prostatectomy for low-risk disease progressively decreasing between 2000 and 2010 [6] . It is, however, not known whether there has been a similar migration towards operative intervention in those with higher-risk disease in UK surgical centres.
Since the cancer Improving Outcome Guidelines in 2002, the surgical management of prostate cancer in the UK has largely been centralised. As a result, referral and treatment patterns are commonly reflective of practice across a wider geographical region rather than just one hospital, particularly as cases are discussed in a regional multidisciplinary team. Here we present case mix and outcome trends over a 10-year period from one UK tertiary referral centre. Our primary interest was to evaluate the evolution of a prostatectomy service, focusing on stage migration and its impact on oncological outcomes.
Patients and Methods

Study cohort
From 2005 onwards patients who underwent robotic radical prostatectomy at our centre were recruited into an ethically approved prospective study (MREC 01/4/061). Our centre is one of two providing a tertiary referral service to the Anglia Cancer Network covering a population of 2.63 million people and including 9 hospitals trusts.
All patients who underwent RALP surgery from October 2005 until January 2015 were included with the exception of men who underwent salvage RALP. Pre-operative demographic data, biopsy details, clinical stage and PSA level at diagnosis were recorded prospectively for each patient.
Pathological results and subsequent outcome data was recorded for all cases. The operative technique applied has been described in detail previously. [7] All cases were operated on by a 
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intermediate-risk (T2b and/or GS =7 and/or PSA >10-20), or high-risk (≥T2c or PSA >20 or GS 8-10). [8] Pre-operative core-biopsy specimens and RALP specimens were examined by histopathologists with a special interest in uropathology and were subsequently reviewed in the Uro-Oncology modification of the Gleason system [9] . A positive surgical margin (PSM) is defined as malignant cells in direct contact with the inked surface as reported by the uro-pathologist and reviewed in the MDT [10] . Biochemical recurrence (BCR) was defined as a confirmed PSA value of >0.2ng/ml [11] .
Statistical analysis
Data processing and descriptive statistical analysis was performed using MS Excel 2013 (Microsoft, Redmond, Washington, USA). Statistical analysis was performed in StatsDirect (StatsDirect Ltd, England, UK). ANOVA was used to look at mean differences between four groups. Chi square analysis was used to assess difference of distributions in numbers or proportions between groups.
In tables 1 and 2 probability values relate to chi square analysis between all 4 groups, in the text values refer to direct analysis between the earliest and latest era groups. p values are therefore 'chi square p values,' a p value <0.05 was considered statistically significant. 
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Pre-operative clinico-pathological characteristics
Baseline patient characteristics according to time period are listed in Table 1 . The mean age across the entire cohort was 61.5 (range 35-78) years; there was no statistically significant difference in age between the populations in the four era (p=0.91). Overall, the mean pre-operative PSA was 8.5 (range 0.5-89) ng/mL; there were no statistically significant differences in the PSA levels between eras (p=0.10). With regards to the pre-treatment clinical stage, there were statistically significant differences over time, with the proportion of cT1 tumours declining from 64. 
Surgical pathology outcomes
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PSM rates were 35.2% in 2005-8 and 29.5% in 2013-15 (p=0.24) . Finally, we did also analyse lymph node involvement in our study. Of the total number of patients, 1033 (68.9%) underwent lymph node dissection (LND). Pathological evidence of LN involvement increased by era (Table 2 ). There were significant differences in the incidence of metastasis in the LN. With only 1.6% of those who underwent LND in 2005-8 found to have metastasis compared to 12.9% in 2013-5 (P<0.0001).
However we interpret this with caution given the changes in lymph node dissection usage and extent across the series.
Surgical outcomes
There were two peri-operative mortalities in this series, one man of myocardial infarction in theatre recovery, and a second dying at home on day 13 post-operation from a presumed pulmonary embolism. Follow-up and BCR data was available for 1358 (90.5%) men, with a mean(range) follow up of 36.1(0-97) months. 92 men were excluded as they underwent immediate adjuvant radiation therapy. Overall 114 patients (8.4%) developed BCR during the follow-up period, this was associated with pathological tumour stage, with 5.98% of pT2 and 22.1% of pT3b patients experiencing BCR (p<0.0001). The follow-up is insufficient to draw conclusions on long-term outcomes but initial 1-year BCR rates are encouraging at 3.9%, 2.4% and 3.4% for the first 3 eras.
Discussion
In the UK there has been a significant increase in the use of surgery for intermediate and high risk PCa since the 1990s despite a lack of randomised evidence to suggest efficacy when compared to other forms of treatment [4, 5, 12, 13] . Data from large observational cohort studies have suggested that surgery may improve outcomes in men with localised disease but this is most evident in younger patients with higher risk disease [14, 15] . Work from our own centre also suggests that this may be true in a UK population [4] . In a study of over 4700 men, surgery appeared to provide superior cancer specific mortality outcomes but specifically in younger men and with high-risk disease. These data are also supported by national opinions on radical therapy usage from UK urologists and oncologists [16] . As our unit's practice is based on a regional referral structure, it is likely to be indicative of the preferences and opinions of prostate cancer specialists from a number of different hospital. Our results have suggested evidence for an increase in the proportion of preoperative high-risk patients undergoing surgery and a concomitant fall in number of cases referred with low-risk disease. Although we did not observe any change in presenting age,
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the median age in our study was already low at 61 years. This is also reflected in an increase in the final pathologic staging characteristics across the series. In the most recent era, the proportion of pT3 disease was in excess of 50% which is considerably higher than other contemporary international series [17, 18] . Encouragingly, this change has not affected surgical margin rates. In fact we observed modest trends towards improved margin free rates in both pT2 and pT3 cases.
The explanation for this shift in tumour characteristics is likely to be multi-factorial, including an increasing appreciation of overtreatment and the use of active surveillance as a valid treatment option. Another contributing factor is the maturation of our robotic prostatectomy service and increased experience of our surgeons. This is the first report demonstrating this shift in population in a UK RRP series. 
There are of course inherent limitations in our study. This study has focused on those PCa patients managed surgically and we have not sought to quantify any changing enrollment to active surveillance or radiotherapy which would predominantly occur at patients' local hospitals, prior to referral for surgery. We have however previously reported regional changes in trends for nonsurgical management of prostate cancer, [4] and expect our results reflect this increasing confidence and use of conservative management. We have also not sought to study continence or potency outcomes in this study. Results from an earlier paper in this cohort have already been published and we do not yet have complete outcome data for the most recent men in this series [7] . Our findings may also not be representative of national trends, although there is no reason to expect significant differences in uptake of national guidelines. Margin status is associated with surgical experience and therefore we might expect a relatively higher incidence among individual surgeons. However in a recent report, we observed no difference in the SM rates in consultants starting their series at different time points in our cohort [20] . Lastly, longer term outcomes are required to fully assess the changing use of RALP in high-risk patients and forms part of our ongoing data collection. Encouragingly, the number of men experiencing BCR in our cohort was low, although we have insufficient follow up to draw conclusions on long-term outcomes. Few comparable series have published BCR rates, the aforementioned Canadian series report 4.9% BCR rate over a median follow-up of 18 months [17] , whilst an American series in 2005 published a 5% 1-year BCR rate amongst a lower-risk group [21].
In summary this paper demonstrates first evidence of reverse stage migration and a shift toward operating on higher-risk PCa in a UK tertiary referral centre. Despite this change, PSM rates have remained unchanged and short term BCR rates are encouraging. Our data reflect an emerging selection preference for performing surgery in men with higher-risk disease which is consistent with evidence of the oncological efficacy of this approach. This further suggests that surgical overtreatment may be gradually becoming less of a problem in our Institution and very likely in the rest of the UK. Further work should seek to confirm these findings in other UK Institutions and further investigation is required to evaluate the impact of this change on long-term oncologic outcomes.
